Practice
Featured experience
Evergy $1.2 billion at-the-market offering
We advised the forward counterparties on the offering
CoreWeave $2.6 billion convertible senior notes offering
We advised CoreWeave on the offering
Kroger $5 billion accelerated share repurchase
Kroger will receive an initial delivery of approximately 65.6 million shares
PPL $1.15 billion equity units offering
We advised PPL on the transaction
Digicel cash tender offer
We advised Digicel in connection with the cash tender offer
iQIYI $1.5 billion concurrent convertible notes and equity offerings
Davis Polk advised the joint book-running managers in connection with concurrent SEC-registered offerings by iQIYI, Inc…
Zynga $874.5 million convertible senior notes offering
Davis Polk advised the representatives of the initial purchasers in connection with a Rule 144A offering by Zynga Inc…
MicroStrategy $650 million convertible senior notes offering
Davis Polk advised the initial purchaser in connection with a Rule 144A offering by MicroStrategy Incorporated of $650…
NextEra Energy Partners $600 million convertible senior notes offering
Davis Polk acted as special product counsel to the initial purchaser in connection with a Rule 144A offering by NextEra…
Esperion Therapeutics $250 million convertible senior subordinated notes
Davis Polk advised the representatives of the initial purchasers in connection with a Rule 144A offering by Esperion…
Microchip Technology $1.1 billion convertible notes exchanges
Davis Polk is advising the financial adviser to Microchip Technology Incorporated in connection with Microchip’s privately…
LendingTree $872 million secondary offering
Davis Polk advised LendingTree, Inc. in connection with the $872 million secondary offering of 2,955,984 shares of its…
Morgan Stanley restarts financing and structured product programs
Davis Polk advised Morgan Stanley on the recommencement of its SEC-registered financing programs and the related filing of…
NovoCure $575 million convertible senior notes offering
Davis Polk advised the representatives of the initial purchasers in connection with a Rule 144A offering by NovoCure Limited…